Exopharm is a step closer to being granted a US patent for the LEAP technology.
The USPTO has issued a ‘Notice of Allowance Mailed’ note for the LEAP patent application (Application 17/147,033). At this point, a USPTO patent number has not been issued in relation to the Application and there are some formalities that need to be completed.
Dr Ian Dixon, founder and CEO and a co-inventor of the LEAP technology said, “We have been working steadily and carefully to secure a US Patent for LEAP – a technology we think could become the global standard for purifying exosome medicines.” He added “The Notice of Allowance is a good and positive sign of progress towards that goal, but there are some further steps before we get there.”